109 related articles for article (PubMed ID: 17505410)
1. Insulin-like growth factor-1 for severe growth failure.
Med Lett Drugs Ther; 2007 May; 49(1261):43-4. PubMed ID: 17505410
[No Abstract] [Full Text] [Related]
2. Advances in pediatric growth hormone therapy: IGF-I-based dosing.
Pawlikowska-Haddal A; Cohen P
Indian Pediatr; 2006 Jul; 43(7):577-81. PubMed ID: 16891676
[No Abstract] [Full Text] [Related]
3. Treatment perspectives in idiopathic short stature with a focus on IGF-I deficiency.
Rosenthal S; Cohen P; Clayton P; Backeljauw P; Bang P; Ten S
Pediatr Endocrinol Rev; 2007 May; 4 Suppl 2():252-71. PubMed ID: 17581497
[No Abstract] [Full Text] [Related]
4. Mecasermin: new drug. Insufficient improvement in statural growth.
Prescrire Int; 2009 Jun; 18(101):111-3. PubMed ID: 19637420
[TBL] [Abstract][Full Text] [Related]
5. The role of recombinant insulin-like growth factor I in the treatment of the short child.
Rosenbloom AL
Curr Opin Pediatr; 2007 Aug; 19(4):458-64. PubMed ID: 17630612
[TBL] [Abstract][Full Text] [Related]
6. Mecasermin Tercica.
Norman P
Curr Opin Investig Drugs; 2006 Apr; 7(4):371-80. PubMed ID: 16625824
[TBL] [Abstract][Full Text] [Related]
7. Anaphylactic reaction to recombinant insulin-like growth factor-I.
Torjusen E; Calderon J; Rivkees SA
J Pediatr Endocrinol Metab; 2008 Apr; 21(4):381-4. PubMed ID: 18556970
[TBL] [Abstract][Full Text] [Related]
8. Recombinant human insulin-like growth factor-1 treatment: ready for primetime.
Bright GM; Mendoza JR; Rosenfeld RG
Endocrinol Metab Clin North Am; 2009 Sep; 38(3):625-38. PubMed ID: 19717008
[TBL] [Abstract][Full Text] [Related]
9. Statement 5: the first line of treatment for children with idiopathic short stature (ISS) and low serum insulin-like growth factor-I (IGF-I) should be IGF-I.
Backeljauw P
Pediatr Endocrinol Rev; 2008 Apr; 5 Suppl 3():853-6. PubMed ID: 18438329
[No Abstract] [Full Text] [Related]
10. [Hormones and osteoporosis update. Growth hormone and bone].
Tanaka H
Clin Calcium; 2009 Jul; 19(7):984-9. PubMed ID: 19567995
[TBL] [Abstract][Full Text] [Related]
11. Pleiotropic action of insulin-like peptides of mollusk, Anodonta cygnea.
Shipilov VN; Shpakov AO; Rusakov YI
Ann N Y Acad Sci; 2005 Apr; 1040():464-5. PubMed ID: 15891090
[TBL] [Abstract][Full Text] [Related]
12. Recombinant human insulin-like growth factor-I therapy for children with growth disorders.
Richmond EJ; Rogol AD
Adv Ther; 2008 Dec; 25(12):1276-87. PubMed ID: 19066756
[TBL] [Abstract][Full Text] [Related]
13. Defining insulin-like growth factor-I deficiency.
Ranke MB
Horm Res; 2006; 65 Suppl 1():9-14. PubMed ID: 16508328
[No Abstract] [Full Text] [Related]
14. Growth hormone testing and the short child.
Guyda HJ
Pediatr Res; 2000 Nov; 48(5):579-80. PubMed ID: 11044473
[No Abstract] [Full Text] [Related]
15. Insulin-like growth factor I and growth responses during the first year of growth hormone treatment in KIGS patients with idiopathic growth hormone deficiency, acquired growth hormone deficiency, turner syndrome and born small for gestational age.
Cutfield WS; Lundgren F
Horm Res; 2009 Jan; 71 Suppl 1():39-45. PubMed ID: 19153504
[TBL] [Abstract][Full Text] [Related]
16. Comparative effects of SPRM asoprisnil (J867) on proliferation, apoptosis, and the expression of growth factors in cultured uterine leiomyoma cells and normal myometrial cells.
Ohara N; Morikawa A; Chen W; Wang J; DeManno DA; Chwalisz K; Maruo T
Reprod Sci; 2007 Dec; 14(8 Suppl):20-7. PubMed ID: 18089606
[TBL] [Abstract][Full Text] [Related]
17. Type I insulin-like growth factor receptor signaling in skeletal muscle regeneration and hypertrophy.
Philippou A; Halapas A; Maridaki M; Koutsilieris M
J Musculoskelet Neuronal Interact; 2007; 7(3):208-18. PubMed ID: 17947802
[TBL] [Abstract][Full Text] [Related]
18. Recombinant human insulin-like growth factor I (rhIGF-I) and rhIGF-I/rhIGF-binding-protein-3: new growth treatment options?
Rosenbloom AL
J Pediatr; 2007 Jan; 150(1):7-11. PubMed ID: 17188604
[No Abstract] [Full Text] [Related]
19. Solution structure of ectodomains of the insulin receptor family: the ectodomain of the type 1 insulin-like growth factor receptor displays asymmetry of ligand binding accompanied by limited conformational change.
Whitten AE; Smith BJ; Menting JG; Margetts MB; McKern NM; Lovrecz GO; Adams TE; Richards K; Bentley JD; Trewhella J; Ward CW; Lawrence MC
J Mol Biol; 2009 Dec; 394(5):878-92. PubMed ID: 19835884
[TBL] [Abstract][Full Text] [Related]
20. Treatment approaches of growth failure.
Rappaport R
Pediatr Endocrinol Rev; 2008 Dec; 6(2):257. PubMed ID: 19209477
[No Abstract] [Full Text] [Related]
[Next] [New Search]
